The impact of menopausal hormone therapy on the incidence of different breast cancer types - Data from the Cancer Registry Hamburg 1991-2006

Cancer Epidemiology

Volumn 34, Issue 5, 2010, Pages 639-643

  Hentschel, S ^a   Heinz, J ^b   Schmid Hopfner S ^a   Obi, N ^b   Vettorazzi, E ^b   Chang Claude, J ^c   Flesch Janys, D ^a  

^a Hamburg Cancer Registry   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Breast cancer; Cancer registry; Ductal carcinoma; Hormone replacement therapy; Lobular carcinoma; Menopausal hormone therapy

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER REGISTRY; CONTROLLED STUDY; DRUG USE; FEMALE; GERMANY; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENOPAUSAL SYNDROME; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; GERMANY; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MENOPAUSE; MIDDLE AGED; POISSON DISTRIBUTION; REGISTRIES; REGRESSION ANALYSIS;

EID: 77957224543     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2010.07.010     Document Type: Article

References (35)

1. Writing Group for the Women's Health Initiative Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomised controlled trial. JAMA 2002, 288(3):321-333.
2. Jemal A., Ward E., Thun M.J. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007, 9(3):R28.
3. Glass A.G., Lacey J.V., Carreon J.D., Hoover R.N. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007, 99(15):1152-1161.
4. Stewart S.L., Sabatino S.A., Forster S.L., Richardson L.C. Decline in breast cancer incidence - United States 1999-2003. MMWR 2007, 56:549-553.
5. Kerlikowske K., Miglioretti D.L., Buist D.S.M., Walker R., Carney P.A. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 2007, 99(17):1335-1339.
6. Robbins A.S., Clarke C.A. Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol 2007, 25(23):3437-3439.
7. Katalinic A., Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 2008, 107(3):427-430.
8. Katalinic A., Stegmaier C., Rawal R., Waldmann A. Weniger Hormonersatztherapie, weniger Brustkrebs in Deutschland?. Geburtshilfe und Frauenheilkunde 2007, (11):1217-1221.
9. Chlebowski R.T., Kuller L.H., Prentice R.L., Stefanick M.L., Manson J.E., Gass M., et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009, 360(6):573-587.
10. Brewster D.H., Sharpe K.H., Clark D.I., Collins J. Declining breast cancer incidence and decreased HRT use. Lancet 2009, 373(9662):459-460.
11. Parkin D.M. Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy?. Eur J Cancer 2009, 45(9):1649-1653.
12. Cancer in Germany, 2003-2004. Incidence and Trends 2008, 6th ed.
13. Flesch-Janys D., Slanger T., Mutschelknaus E., Kropp S., Obi N., Vettorazzi E., et al. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 2008, 123(4):933-941.
14. Ravdin P.M., Cronin K.A., Howlader N., Chlebowski R.T., Berry D.A. A sharp decrease in breast cancer incidence in the United States in 2003. Breast Cancer Res Treat 2006, 100(Suppl. 1):S6.
15. Ravdin P.M., Cronin K.A., Howlader N., Berg C.D., Chlebowski R.T., Feuer E.J., et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007, 356(16):1670-1674.
16. Kliewer E.V., Demers A.A., Nugent Z.J. A decline in breast-cancer incidence. N Engl J Med 2007, 357(5):509-510.
17. Colditz G.A. Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin. Breast Cancer Res 2007, 9(4):108.
18. Zahl P.H., Maehlen J. A decline in breast-cancer incidence. N Engl J Med 2007, 357(5):510-511.
19. Ponti A., Rosso S., Zanetti R., Ricceri F., Tomatis M., Segnan N. Re: breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007, 99(23):1817-1818.
20. Soerjomataram I., Coebergh J.W., Louwman M.W.J., Visser O., van Leeuwen F.E. Does the decrease in hormone replacement therapy also affect breast cancer risk in the Netherlands?. J Clin Oncol 2007, 25(31):5038-5039.
21. Robbins A.S., Clarke C.A. Re: declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 2007, 99(23):1815-1817.
22. Canfell K., Banks E., Moa A.M., Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 2008, 188(11):641-644.
23. Bouchardy C., Fioretta G., Verkooijen H.M., Vlastos G., Schaefer P., Delaloye J.-F., et al. Recent increase of breast cancer incidence among women under the age of forty. Br J Cancer 2007, 96(11):1743-1746.
24. Hery C., Ferlay J., Boniol M., Autier P. Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations. Ann Oncol 2008, 19(6):1187-1194.
25. Clarke C.A., Glaser S.L., Uratsu C.S., Selby J.V., Kushi L.H., Herrinton L.J. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 2006, 24(33):e49-e50.
26. Chen C.L., Weiss N.S., Newcomb P., Barlow W., White E. Hormone replacement therapy in relation to breast cancer. JAMA 2002, 287(6):734-741.
27. Daling J.R., Malone K.E., Doody D.R., Voigt L.F., Bernstein L., Coates R.J., et al. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 2002, 95(12):2455-2464.
28. Li C.I., Weiss N.S., Stanford J.L., Daling J.R. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 2000, 88(11):2570-2577.
29. Vankrunkelsven P., Kellen E., Lousbergh D., Cloes E., Op de Beeck L., Faes C., et al. Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg. Breast Cancer Res Treat 2009, 118:425-432.
30. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P. Cancer incidence in five continents. IARC Scientific Publications No. 160, 2007; vol. IX. p. 307.
31. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362:419-427.
32. Koch K. Hormonersatz-Therapie: Rechnung mit Unbekannten. Dtsch Ärzteblatt 2000, 97(33):A-2145-A-2146.
33. Koch K., Greiser E. Hormonersatz-Therapie: Rechnung mit Unbekannten. Dtsch Ärztbl 2000, 97(39):A-2512.
34. Biglia N., Mariani L., Robba C., Moggio G., Sismondi P. Hormone-replacement therapy and lobular cancers: new deals and old myths. Expert Rev Endocrinol Metab 2008, 3(3):287-290.
35. Weedon-Fekjaer H., Sørum R., Brenn M.K. Hormone therapy use may explain recent results regarding tumor regression. Arch Intern Med 2009, 169(May (10)):996-997.